|Oncothyreon (ONTY) Price Target Lowered to $3 at Wedbush|
"While we are removing tecemotide from our valuation, we are adding the opportunity for ONTY's newly acquired protocell technology in primary hyperoxaluria type 1 (PH-1). Protocell technology, gained as part of the recent Alpine Biosciences acquisition ...
StreetInsider.com (subscription) - Tue, 19 Aug 2014 05:33
|Dicerna Provides Operational Update and Reports Second Quarter 2014 ...|
DCR-PH1 is a therapeutic candidate for Primary Hyperoxaluria 1 (PH1), a rare, inherited autosomal recessive disorder of metabolism in the liver that usually results in life-threatening damage to the kidneys. In the genetic mouse model of PH1, Dicerna ...
Business Wire (press release) - Thu, 07 Aug 2014 12:52
|Dicerna On Track with Drug Candidates, Initial Cancer Rx Data Expected in '15|
NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track ...
GenomeWeb - Thu, 21 Aug 2014 07:30
Last update: September 2014